Bone marrow as a source of hematopoietic stem cells for human gene therapy of β-thalassemia.
暂无分享,去创建一个
M. Roncarolo | G. Ferrari | F. Ciceri | M. Frittoli | S. Marktel | B. Cappelli | E. Biral | M. Zambelli
[1] Jérôme Larghero,et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.
[2] G. Tonon,et al. Correction of β-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients , 2010, EMBO molecular medicine.
[3] Frederic D. Bushman,et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. , 2010, The New England journal of medicine.
[4] J. Dipersio,et al. Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells , 2010, Current opinion in hematology.
[5] E. Yannaki,et al. Mobilization of hematopoietic stem cells in a thalassemic mouse model: implications for human gene therapy of thalassemia. , 2010, Human gene therapy.
[6] Alessandro Aiuti,et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.
[7] Manfred Schmidt,et al. Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.
[8] Tso-fu Wang,et al. Correlation between characteristics of unrelated bone marrow donor and cell density of total nucleated cell in bone marrow harvest , 2009, International journal of hematology.
[9] P. Telfer. Update on Survival in Thalassemia Major , 2009, Hemoglobin.
[10] N. Schmitz,et al. Severe events in donors after allogeneic hematopoietic stem cell donation , 2009, Haematologica.
[11] M. Cappellini,et al. Thalassemia and hypercoagulability. , 2008, Blood reviews.
[12] A. Miccio,et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of β-thalassemia , 2008, Proceedings of the National Academy of Sciences.
[13] G. Federici,et al. Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia. , 2008, Blood transfusion = Trasfusione del sangue.
[14] A. Pession,et al. Collection and transfer of data: the AIEOP model , 2008, Bone Marrow Transplantation.
[15] Matthew Darlison,et al. Global epidemiology of haemoglobin disorders and derived service indicators. , 2008, Bulletin of the World Health Organization.
[16] G. Lucarelli,et al. Advances in the allogeneic transplantation for thalassemia. , 2008, Blood reviews.
[17] M. Minden,et al. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] J. Dipersio,et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[19] S. Rivella,et al. Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. , 2006, Human gene therapy.
[20] C. Dunbar,et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. , 2006, Blood.
[21] Yang Du,et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.
[22] Arnon Nagler,et al. Weighing the risks of G‐CSF administration, leukopheresis, and standard marrow harvest: Ethical and safety considerations for normal pediatric hematopoietic cell donors , 2006, Pediatric blood & cancer.
[23] A. Cnaan,et al. Survival and Complications in Thalassemia , 2005, Annals of the New York Academy of Sciences.
[24] T. Hirasawa,et al. Effect of peripheral blood progenitor cell dose on hematopoietic recovery: identification of minimal progenitor cell requirements for rapid engraftment , 2004, Bone Marrow Transplantation.
[25] A. Cnaan,et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.
[26] V. Jiménez‐Yuste,et al. Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors. , 2002, Journal of hematotherapy & stem cell research.
[27] A. Eldor,et al. The hypercoagulable state in thalassemia. , 2002, Blood.
[28] C. Demers,et al. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors , 1999, Bone Marrow Transplantation.
[29] T. Leung,et al. Granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in beta-thalassemia patients: kinetics of mobilization and composition of apheresis product. , 1999, Experimental hematology.
[30] F. Aversa,et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor , 1999, The Lancet.
[31] J Wagner,et al. Clonogenic capacity andex vivo expansion potential of umbilical cord blood progenitor cells are not impaired by cryopreservation , 1997, Bone Marrow Transplantation.
[32] S. Rowley,et al. Long-term cryopreservation of bone marrow for autologous transplantation. , 1996, Bone marrow transplantation.
[33] M. Harada,et al. Predominance of myeloid antigens in CD34‐positive peripheral blood stem cells over those in bone marrow after administration of granulocyte colony‐stimulating factor , 1994, European journal of haematology.
[34] M. Andreani,et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. , 1993, The New England journal of medicine.
[35] L. To,et al. Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. , 1991, Blood.